ArticleThe Journal of pediatrics2017
Acylcarnitine Profiles Reflect Metabolic Vulnerability for Necrotizing Enterocolitis in Newborns Born Premature.
Article in The Journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Beyond early diagnosis: toward AI-enabled multi-omics prediction of necrotizing enterocolitis.World journal of pediatrics : WJP · 2026Article
- Quantitative assessment of neonatal health using dried blood spot metabolite profiles and deep learning.Science translational medicine · 2026Article
- Review
- Transgenerational associations between newborn metabolic profiles and bronchopulmonary dysplasia in neonates born to mothers with an obese phenotype.Scientific reports · 2025Article
- L-carnitine: new perspectives on the management of preterm infants.Frontiers in nutrition · 2025Review
- The influence of hypertensive disorders in pregnancy on neonatal amino acid and acylcarnitine levels.Frontiers in nutrition · 2025Article
- Metabolomic analysis to predict the onset and severity of necrotizing enterocolitis.BMC gastroenterology · 2024Article
- Struggling to Understand the NEC Spectrum-Could the Integration of Metabolomics, Clinical-Laboratory Data, and Other Emerging Technologies Help Diagnosis?Metabolites · 2024Review
- Immunological aspects of necrotizing enterocolitis models: a review.Frontiers in immunology · 2024Review
- Metabolomics in NEC: An Updated Review.Metabolites · 2023Review
- The Urinary Metabolomic Fingerprint in Extremely Preterm Infants on Total Parenteral Nutrition vs. Enteral Feeds.Metabolites · 2023Article
- Butyrate induces development-dependent necrotizing enterocolitis-like intestinal epithelial injury via necroptosis.Pediatric research · 2023Article
- State-of-the-art review and update ofFrontiers in pediatrics · 2023Review
- Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2022Article
- Progressive Metabolic Abnormalities Associated with the Development of Neonatal Bronchopulmonary Dysplasia.Nutrients · 2022Article
- Newborn screen metabolic panels reflect the impact of common disorders of pregnancy.Pediatric research · 2022Observational
- Immunoreactive Trypsinogen and Free Carnitine Changes on Newborn Screening after Birth in Patients Who Develop Type 1 Diabetes.Nutrients · 2021Article
- Plasma Metabolomics to Evaluate Progression of Necrotising Enterocolitis in Preterm Pigs.Metabolites · 2021Article
- Review
- Hope on the horizon: promising novel therapies for necrotizing enterocolitis.Pediatric research · 2020Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the association between newborn acylcarnitine profiles and the subsequent development of necrotizing enterocolitis (NEC) with the use of routinely collected newborn screening data in infants born preterm. STUDY
designA retrospective cohort study was conducted with the use of discharge records for infants born preterm admitted to neonatal intensive care units in California from 2005 to 2009 who had linked state newborn screening results. A model-development cohort of 94 110 preterm births from 2005 to 2008 was used to develop a risk-stratification model that was then applied to a validation cohort of 22 992 births from 2009.
resultsFourteen acylcarnitine levels and acylcarnitine ratios were associated with increased risk of developing NEC. Each log unit increase in C5 and free carnitine /(C16 + 18:1) was associated with a 78% and a 76% increased risk for developing NEC, respectively (OR 1.78, 95% CI 1.53-2.02, and OR 1.76, 95% CI 1.51-2.06). Six acylcarnitine levels, along with birth weight and total parenteral nutrition, identified 89.8% of newborns with NEC in the model-development cohort (area under the curve 0.898, 95% CI 0.889-0.907) and 90.8% of the newborns with NEC in the validation cohort (area under the curve 0.908, 95% CI 0.901-0.930).
conclusionsAbnormal fatty acid metabolism was associated with prematurity and the development of NEC. Metabolic profiling through newborn screening may serve as an objective biologic surrogate of risk for the development of disease and thus facilitate disease-prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.